↓ Skip to main content

Gene Therapy of Solid Cancers

Overview of attention for book
Cover of 'Gene Therapy of Solid Cancers'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Aptamer Targeting the ERBB2 Receptor Tyrosine Kinase for Applications in Tumor Therapy
  3. Altmetric Badge
    Chapter 2 Gene Gun Her2/neu DNA Vaccination: Evaluation of Vaccine Efficacy in a Syngeneic Her2/neu Mouse Tumor Model.
  4. Altmetric Badge
    Chapter 3 MIDGE Technology for the Production of a Fourfold Gene-Modified, Allogenic Cell-Based Vaccine for Cancer Therapy.
  5. Altmetric Badge
    Chapter 4 Evaluation of Bystander Cell Killing Effects in Suicide Gene Therapy of Cancer: Engineered Thymidylate Kinase (TMPK)/AZT Enzyme-Prodrug Axis
  6. Altmetric Badge
    Chapter 5 Oncoleaking: Use of the Pore-Forming Clostridium perfringens Enterotoxin (CPE) for Suicide Gene Therapy
  7. Altmetric Badge
    Chapter 6 iCaspase 9 Suicide Gene System.
  8. Altmetric Badge
    Chapter 7 p53-Encoding pDNA Purification by Affinity Chromatography for Cancer Therapy
  9. Altmetric Badge
    Chapter 8 A qRT-PCR Method for Determining the Biodistribution Profile of a miR-34a Mimic.
  10. Altmetric Badge
    Chapter 9 Design and Selection of Antisense Oligonucleotides Targeting Transforming Growth Factor Beta (TGF-β) Isoform mRNAs for the Treatment of Solid Tumors.
  11. Altmetric Badge
    Chapter 10 RNA Interference for Antimetastatic Therapy
  12. Altmetric Badge
    Chapter 11 STAT3 Decoy ODN Therapy for Cancer.
  13. Altmetric Badge
    Chapter 12 Oncolytic Viral Therapy Using Reovirus
  14. Altmetric Badge
    Chapter 13 Use of GLV-1h68 for Vaccinia Virotherapy and Monitoring
  15. Altmetric Badge
    Chapter 14 Back to the Future: Are Tumor-Targeting Bacteria the Next-Generation Cancer Therapy? - PubMed - NCBI
  16. Altmetric Badge
    Chapter 15 Ethics of Cancer Gene Transfer Clinical Research
  17. Altmetric Badge
    Chapter 16 Planning an Academic Clinical Trial
  18. Altmetric Badge
    Chapter 17 Production of Plasmid DNA as Pharmaceutical
  19. Altmetric Badge
    Chapter 18 Minicircle: Next Generation DNA Vectors for Vaccination.
  20. Altmetric Badge
    Chapter 19 A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma.
  21. Altmetric Badge
    Chapter 20 Antiangiogenic Metargidin Peptide (AMEP) Gene Therapy in Disseminated Melanoma.
  22. Altmetric Badge
    Chapter 21 Clinical Evaluation of ErbB-Targeted CAR T-Cells, Following Intracavity Delivery in Patients with ErbB-Expressing Solid Tumors.
Attention for Chapter 11: STAT3 Decoy ODN Therapy for Cancer.
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 X user

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
5 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
STAT3 Decoy ODN Therapy for Cancer.
Chapter number 11
Book title
Gene Therapy of Solid Cancers
Published in
Methods in molecular biology, January 2015
DOI 10.1007/978-1-4939-2727-2_11
Pubmed ID
Book ISBNs
978-1-4939-2726-5, 978-1-4939-2727-2
Authors

Sun, Xiaoxia, Zhang, Jian, Xiaoxia Sun, Jian Zhang

Abstract

As an oncogene, over-activated signal transducer and activator of transcription 3 (STAT3) has been detected in many tumors. STAT3 controls cell differentiation, proliferation, and survival, and is associated with angiogenesis and immune dysfunction during tumorigenesis. Double-stranded decoy oligodeoxynucleotide (ODN) targeting over-activated STAT3 in tumor cells have shown significant antitumor efficiency. Here, we describe the materials and methods involved in STAT3 decoy ODN therapy for cancer including both the antitumor effect directly and immunotherapy indirectly.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 5 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 5 100%

Demographic breakdown

Readers by professional status Count As %
Professor 1 20%
Student > Bachelor 1 20%
Student > Postgraduate 1 20%
Unknown 2 40%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 2 40%
Agricultural and Biological Sciences 1 20%
Unknown 2 40%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 March 2016.
All research outputs
#19,015,492
of 23,577,654 outputs
Outputs from Methods in molecular biology
#8,199
of 13,353 outputs
Outputs of similar age
#259,787
of 356,631 outputs
Outputs of similar age from Methods in molecular biology
#504
of 992 outputs
Altmetric has tracked 23,577,654 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 13,353 research outputs from this source. They receive a mean Attention Score of 3.4. This one is in the 24th percentile – i.e., 24% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 356,631 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 992 others from the same source and published within six weeks on either side of this one. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.